Pulmonary hypertension (PH) is a chronic, life-threatening condition involving high blood pressure in the arteries of the ...

门脉性肺动脉高压（portopulmonary hypertension，PoPH）是门静脉高压的一种常见并发症，目前被归为肺动脉高压（pulmonary arterial ...

A systematic review of quality-of-life tools available specifically for pulmonary arterial hypertension (PAH) reveals that ...

Aims Pulmonary hypertension (PHT) appears to be very common in heart failure with preserved ejection fraction but details on ...

After Keros Therapeutics Inc.’s voluntary halt of dosing in two arms of its phase II study in pulmonary arterial hypertension ...

Keros Therapeutics Inc. shares lost over three-quarters of their market capitalization on Thursday, marking an all-time low, ...

Keros Therapeutics has halted dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial ...

Global Pulmonary Arterial Hypertension (PAH) Treatment Market is thriving due to a rising prevalence of pulmonary hypertension, advancements in drug development, increasing awareness about the disease ...

Cibotercept is a fusion protein commercialized by Keros Therapeutics, with a leading Phase II program in Pulmonary Arterial Hypertension.

Merck’s new pulmonary arterial hypertension (PAH) medication has posted another batch of promising clinical trial data, ...

The company said the unanticipated events of pericardial effusion--when fluid builds up in the space around the heart--came in the Phase 2 clinical trial of 3 milligrams per kilogram and 4.6 mg/kg ...